Arix Bioscience
Arix Bioscience, a leading life sciences company headquartered in Great Britain, focuses on advancing innovative therapies in the biotechnology sector. Founded in 2013, Arix has established itself as a key player in the industry, with a strong emphasis on developing and commercialising breakthrough treatments across various therapeutic areas, including oncology and rare diseases. The company is renowned for its unique approach to building and supporting a diverse portfolio of life science companies, leveraging its deep expertise and extensive network. Arix Bioscience's commitment to fostering innovation has positioned it as a prominent venture capital firm, recognised for its strategic investments and successful partnerships. With a robust pipeline of core products and a reputation for excellence, Arix continues to make significant strides in transforming healthcare and improving patient outcomes.
DitchCarbon Score
How does Arix Bioscience's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Research Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Arix Bioscience's score of 7 is higher than 84% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Arix Bioscience's reported carbon emissions
In 2022, Arix Bioscience reported total carbon emissions of approximately 8,890 kg CO2e globally, with 3,680 kg CO2e from Scope 1 and 4,410 kg CO2e from Scope 2 emissions. The company also disclosed Scope 3 emissions of about 5,210 kg CO2e. In the UK, their emissions for the same year were similar, with 3,680 kg CO2e from Scope 1 and a market-based total of 8,890 kg CO2e for Scope 2. Comparatively, in 2020, Arix's total emissions were about 5,110 kg CO2e globally, with 5,020 kg CO2e from Scope 1 and 6,770 kg CO2e from Scope 2, alongside 90 kg CO2e from Scope 3. This indicates a significant reduction in emissions over the two-year period. Despite these reductions, Arix Bioscience has not set specific reduction targets or climate pledges, which may limit their long-term climate strategy. The company continues to monitor and report its emissions, aligning with industry standards for transparency and accountability in climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2017 | 2020 | 2021 | 2022 | |
|---|---|---|---|---|
| Scope 1 | 14,100 | 0,000 | 0,000 | 0,000 |
| Scope 2 | 7,000 | 0,000 | 0,000 | 0,000 |
| Scope 3 | - | 00 | 0,000 | 0,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Arix Bioscience is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
